>if they get patients with even worse reaction or even dying from it, it could kill the therapy for good in Phase I.
Perhaps. Or perhaps not. It depends. If it shows to be safer than a bone marrow transplant (insanely dangerous) its got potential.
It's all a benefits/risk analysis.